Favorable data show that genetic deletion of TRPM2 is well tolerated and does not appear to alter behavior.[33] Our long‐term treatment of mice inoculated with EGFRm NSCLC PDXs with D9 and osimertinib combination for up to 180 days was well tolerated, while exerting a promising delay in the emergence of acquired resistance to osimertinib. The gene discussed is TRPM2; the disease is non-small cell lung carcinoma.